• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
KURA

KURA

Kura Oncology, Inc.

NASDAQHealthcareBiotechnologyUS

USD8.65

-0.32 (-3.51%)

Rating:C

Company Profile

CEO

Troy Edward Wilson

IPO Date

2015-09-16

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$8.95

Prev. Close

$8.97

Day Low

$8.63

Day High

$8.96

52W Low

$5.45

52W High

$12.49

Market Cap

$0.77B

Volume

1.57M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

24.5%

Avg Negative

4.6%

Avg Neutral

71.1%

News Feed

Kura Oncology to Report Second Quarter 2021 Financial Results

GlobeNewsWire·7/29/2021·↑ positive

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

GlobeNewsWire·7/6/2021·↑ positive

Kura Oncology to Participate in JMP Securities Life Sciences Conference

GlobeNewsWire·6/10/2021·↑ positive

Kura Oncology Appoints Carol Schafer to Board of Directors

GlobeNewsWire·6/4/2021·↑ positive

Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

GlobeNewsWire·5/13/2021·↑ positive

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Kura Oncology to Report First Quarter 2021 Financial Results

GlobeNewsWire·4/29/2021·↑ positive

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

GlobeNewsWire·3/22/2021·↑ positive

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·2/24/2021·↓ negative

Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck Cancer

Benzinga·2/24/2021·↑ positive